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Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy
Suzannah J Harnor, Alfie Brennan and Céline Cano*
Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK
Abstract
The catalytic activity of DNA-dependent protein kinase (DNA-PK) is central to its ability to repair lethal DNA-
double strand breaks (DSBs). This includes repair of DSB lesions following therapeutic treatment of cancer cells 
or resulting from oxidative stress or oncogene-induced transcription. As a tactic to induce tumour chemo- and 
radio-sensitisation, numerous attempts have been made to identify small molecule inhibitors of DNA-PK activity. 
This review examines the structures of known reversible and irreversible inhibitors, including those based upon 
chromen-4-one, arylmorpholine, and benzaldehyde scaffolds. VX-984 and M3814 are recent examples of DNA-PK 
catalytic inhibitors that have progressed into clinical development, the results from which should help to further 
advance our understanding of whether this approach represents a promising therapeutic strategy for the treatment 
of cancer.
Keywords: Chemopotentiation; DNA damage response; DNA-PK; 
Inhibitor; Kinase; NHEJ
Introduction
DNA double-strand breaks (DSBs) are a highly toxic form of 
DNA damage that can be caused by reactive oxygen species (ROS) 
naturally occurring in eukaryotic cells as well as exogenous stimuli, 
such as ionising radiation. A key protein involved in the repair of 
these lesions is DNA-dependent protein kinase (DNA-PK). The active 
DNA-PK complex is composed of a catalytic serine/threonine protein 
kinase (DNA-PKcs) and two heterodimeric subunits (Ku70 and Ku80) 
which bind to the DSB and direct the catalytic subunit to the site 
requiring repair [1,2]. Even a single DSB has the potential to cause a 
genomic rearrangement resulting in a mutation that could have fatal 
consequences for the cell. The evolutionary response to this lethality 
has been the development of three independent pathways capable of 
repairing DNA DSBs. Homologous recombination (HR) takes place 
during the S and G2 phases of the cell cycle when sister chromatids are 
available to act as a template, thereby allowing highly accurate repair 
of the genome [3]. Non-homologous end joining (NHEJ) can occur 
throughout the cell cycle, although it is critically important during the 
G1 phase before DNA replication, allowing cells to constantly maintain 
genomic integrity [4-6]. The third pathway, microhomology-mediated 
end joining (MMEJ), is a mutagenic process that only occurs when a 
cell is unable to effectively utilise HR and NHEJ. The kinase activity 
of DNA-PK has been shown to be critically important for effective 
NHEJ to take place. Once the Ku heterodimer has bound to the site of 
a DSB, recruitment of the DNA-PKcs takes place leading to a shift in 
the conformation of the heterodimer which simultaneously tethers the 
broken ends of the strands together and stimulates kinase activity [7,8]. 
DNA-PKcs has been shown to have altered activity and expression in 
several tumour types. Studies in chronic lymphocytic leukaemia (CLL) 
have demonstrated that increased DNA-PKcs activity correlated with 
resistance to DNA damage inducing chemotherapeutics and reduced 
treatment free interval [9,10]. Elevated DNA-PKcs expression has also 
been reported in gastric cancer [11] and found to correlate with poor 
patient prognosis in ovarian cancer [12] and hepatocellular carcinoma 
(HCC) [13]. The evidence identifying DNA-PK as a key marker for 
treatment resistant tumours has driven many attempts to find suitable 
inhibitors of DNA-PKcs kinase activity. DNA-PK is a large (555 kDa), 
multi-component enzyme and as such has proved a highly challenging 
target for structural biology - often a crucial facet of modern drug 
discovery campaigns. As such, campaigns to identify potent inhibitors 
have relied upon more traditional screening and optimisation 
processes. Inhibitors so far identified have varied widely with respect 
to potency, selectivity, and reversibility - although all have been type 1 
inhibitors competing directly with the ATP binding site of the catalytic 
domain. DNA-PKcs is a member of the phosphatidylinositol 3-kinase 
related kinase (PIKK) family, which includes proteins such as ATM 
(Ataxia telangiectasia mutated kinase), ATR (AT and Rad3-related 
kinase), and mTOR (Mammalian Target of Rapamycin) all of which 
have been the targets of anti-cancer drug discovery efforts - including 
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the development of several clinical candidates [4-6]. Good selectivity 
over these enzymes is therefore essential before a tool compound can 
be used to accurately assess the in vivo relevance of DNA-PK inhibition.
DNA-PK Small Molecule Inhibitors
Wortmannin
Wortmannin (1) is a natural fungal metabolite, derived from 
Penicillium wortmannii K and first observed to have antifungal and 
anti-inflammatory properties. This steroidal derivative is a potent and 
selective inhibitor of PI3K family kinases without activity against other 
intracellular signalling enzyme targets, inhibiting PI3K activity with an 
IC50 of 4.2 nM [14] (Scheme 1).
Kinetic analysis of the PI3K inhibition by wortmannin indicated 
a non-competitive irreversible inhibition, further verified with co-
crystallographic studies of the resulting covalent complex in the ATP-
binding pocket of PI3Kγ [15,16]. Subsequent work demonstrated 
that wortmannin also inhibits DNA-PK (IC50=16 nM) by a non-
competitive mechanism, forming covalent adducts with DNA-PKcs 
lysine 802 in the region of the molecule harbouring its kinase domain 
[17]. Although the activity of this sterol-like structure and its mode of 
interaction made it an interesting early tool compound, the relative 
structural complexity of wortmannin, together with its irreversible 
inhibition and poor selectively, limit its potential as a drug molecule. 
Despite these limitations, wortmannin was used to demonstrate a 3-5-
fold enhancement of IR-induced cytotoxicity and an inhibition of IR-
induced DSB repair in Chinese hamster ovary cells [18].
Chromen-4-ones and surrogates: LY2094002 and derivatives
In the early 1990’s, Lilly pharmaceuticals undertook a screen of 
compounds derived from quercetin (2), with the objective of developing 
PI3K-specific inhibitors. The chromen-4-one structure LY294002 (3) 
was reported as an inhibitor of PI3K [19] (Scheme 2).
Subsequent evaluation of 3 as a DNA-PK inhibitor, showed that the 
compound exhibited similar DNA-PK inhibitory activity to that against 
PI3K, highlighting the non-selective profile of the compound (Table 1) 
[19,20].
The importance of the oxygen of the morpholine substituent of 3 
was verified, and while replacement by thiomorpholine (4) dramatically 
reduced potency, the piperidine derivative 5 proved essentially devoid 
of DNA-PK inhibitory activity. The key role of the morpholine 
substituent of 3 was later substantiated by X-ray crystallography, 
when the structure of 3 in complex with human PI3Kγ revealed that 
the morpholine oxygen makes a hydrogen bond interaction with the 
backbone amide group of Val-882 within the ATP-binding domain of 
the kinase (Figure 1) [16].
Despite suffering from high clearance (1h) and in vivo toxicity, 3 
aided in the development of derivatives with improved potency and 
selectivity against DNA-PK, and superior physicochemical properties. 
Research conducted at the Northern Institute for Cancer Research at 
Newcastle University in collaboration with KuDOS Pharmaceuticals 
investigated a series of benzopyranones and pyrimidoisoquinolinones 
[20]. Incorporation of a fused ring on the chromenone, gave a 5-fold 
improvement in potency against DNA-PK (NU7026 (6); DNA-PK 
IC50=0.23 µM) (Table 2) and introduction of a methyl group on the 
morpholine ring was equipotent (7; DNA-PK IC50=0.19 µM). Additional 
methyl groups, at the 2 or 6-position of morpholine, or replacement of 
the morpholine ring altogether (e.g., piperidine, piperazine) resulted 
in a loss of activity [20,21]. These early derivatives showed better 
selectivity for DNA-PK over other PIKK family members than the 
parent compound, e.g., 6 is 60-fold more potent against DNA-PK than 
PI3K (p110α) (Table 2 and Scheme 3).
Replacement of the chromen-4-one scaffold by the isosteric 
pyrimidoisoquinolinone structure gave equipotent compounds (8; 
IC50=0.28 µM) [22]. Multiple studies have revealed that 6 acts in vitro as 
a radiosensitiser, [23] and as a chemo-potentiator of topoisomerase II 
(TOP2) poisons in human leukaemia cell lines [24].Scheme 1: Wortmannin.
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Figure 1: Crystal structure of LY294002 (3) in complex with the ATP-binding 
domain of PI3Kγ.
Table 1: Reported inhibitory activity of LY294002 (3) against different PIKK family 
members.
aValues from Ref [19]; bLiterature value from Ref [20]
PIKK DNA-PK PI3K (p110α) ATM ATR mTOR
IC50(µM) 1.5 ± 0.2a 2.3 ± 0.8a (1.4)b >100a >100a 2.5 ± 0.2a
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In a bid to simplify the chromenone core, synthesis of a series of 
substituted monocyclic pyran-2-one, pyran-4-one, thiopyran-4-one 
and pyridin-4-one derivatives was carried out [25]. The pyran-4-one 
system and substitution at the pyranone 3- or 5-positions gave a loss 
of activity. However, library work on 6-substituted-2-morpholino-
pyran-4-one and 6-substituted-2-morpholinothiopyran-4-one, led to 
the identification of 9 (DNA-PK; IC50=0.18 µM) and 10 (DNA-PK 
IC50=0.19 µM), both 10-fold more potent against DNA-PK than the 
parent 3 [25,26] (Scheme 4).
Significant improvement in potency and selectivity against 
DNA-PK was attained as a result of a multi-parallel library approach 
to synthesise 6-, 7- and 8-aryl substituted chromen-4-ones [27]. 
Interestingly, compound 11 (DNA-PK IC50=0.11 µM) showed a 10-
fold increase in potency compared to 3, whereas the dibenzofuranyl 
derivative (12) (DNA-PK IC50=0.04 µM) was the first sub-micromolar 
inhibitor of DNA-PK. The incorporation of a dibenzothiophenyl group 
led to NU7441 (13), a compound with a 100-fold increase in potency 
compared with the parent phenyl derivative 3 (DNA-PK IC50=0.02 µM), 
along with excellent selectivity over other PIKK family members (Table 3).
Characterisation using the SW620 and LoVo cell lines found that 
1 µM 13 enhanced the cytotoxicity of TOP2 inhibitors etoposide (2- to 
12-fold) and doxorubicin (2- to 10-fold) as well as ionising radiation 
(IR) (2- to 4-fold) [28]. Importantly, in vivo studies showed that even 
with relatively poor solubility, 13 increased etoposide-induced tumour 
growth delay in the SW620 tumour xenograft model [28].
An homology model of the ATP-binding site of DNA-PK, 
derived from the crystal structure of PI3Kγ was used to guide further 
inhibitor design [29]. The model predicted that groups substituted at 
the dibenzothiophene 1-position of 13, would be directed out of the 
binding pocket into bulk solvent (Figure 2A, red arrow).
The newly synthesised compounds all possessed polar substituents 
at the dibenzothiophene 1-position, with an aim to improve potency 
and physicochemical properties [30]. A number of the compounds 
exhibited high potency against DNA-PK and potentiated the cytotoxicity 
of IR in vitro 10-fold or more (e.g., 14; DNA-PK IC50=5.0 ± 1 nM, IR 
dose modification ratio=13). Furthermore, 14 was shown to potentiate 
not only IR in vitro but also DNA-inducing cytotoxic anticancer agents, 
both in vitro and in vivo. A counter-screen against other members 
of the PI3K PIKK family revealed that some of the compounds were 
potent mixed DNA-PK and PI3K inhibitors, including 14 [30,31]. The 
favourable biological activity of 14 was complemented by superior 
drug-like properties compared to NU7441 (13), and acceptable plasma 
protein binding, combined with weak activity against hERG and a panel 
of cytochrome P450 (CYP) drug-metabolising enzymes (Table 4) [30].
[a] Amorphous material (crystalline solubility at pH7.4 buffer=6.0 μM)
[b] Tested in CYP 3A4, 2D6, 2C9, 2C19 and 1A2
In efforts to optimise the biological and pharmaceutical properties 
of 13, and to expand structure-activity relationships (SARs), the core 
chromenone scaffold as well as the dibenzothiophen-4-yl moiety have 
been systematically modified [32,33]. As 11 is approximately 10-fold 
more potent than the parent 8-phenylchromenone (3) this strongly 
indicated that the 3-phenyl substituent of 11 made additional binding 
interactions within the ATP-binding domain of DNA-PK. By probing 
this presumed binding interaction further, replacement of the 3-phenyl 
group of 11 by an isosteric thiophen-2-yl substituent (15) improved 
DNA-PK inhibitory activity approximately 10-fold (DNA PK; IC50=18 
nM) [32]. Homology modelling studies indicated that the heteroaryl 
substituent may occupy a putative hydrophobic pocket, with further 
SAR resulting in the discovery of O-alkoxyphenylchromen-4-one (16) 
(DNA PK; IC50=8 nM) [32,33].
Resolvable atropisomeric derivatives of 3 have also been described. 
Introduction of a methyl substituent, as a representative example, 
at the dibenzothiophene 3-position (17) (DNA PK; IC50=1.7 µM) or 
at the chromenone 7-position (18) (DNA PK; IC50=0.005 µM) of 13, 
generated stable pairs of atropisomers due to restricted rotation between 
the chromen-4-one and dibenzothiophene rings [29,34]. Substitution 
DNA-PK PI3K (p110α) ATM ATR mTOR
6 0.23 13 >100 >100 6.2
7 0.19 2.4 >100 >100 4.8
8 0.28 >100 >100 >100 5.3
Table 2: Inhibitory activity (IC50 µM) against different PIKK family members [20].
Scheme 3: potency against DNA-PK (NU7026 (6); DNA-PK IC50=0.23 µM).
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Scheme 4: Incorporation of a dibenzothiophenyl group led to NU7441 (13).
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Figure 2: Homology model of the ATP-binding site of the DNA-Dependent 
Protein Kinase (DNA-PK) used to guide inhibitor design [29]. The 3D model 
was constructed on the basis of the known X-ray crystal structure of PI3Kγ 
from RCSB protein data bank (PDB ID: 1E7V) as a template, and with DNA-
PK sequence from Swiss-Port (ID: PRKDC_DICDI) using Prime in Maestro 
molecular modelling program (licensed from Schrödinger, LGG).  NU7441 (13) 
is represented in (A) an orthogonal, and (B) ‘in plane’ pose.
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at the dibenzothiophene 3-position (17) resulted in an approximately 
60-fold reduction in potency of the racemic compound against DNA-
PK compared with the parent compound (13). Interestingly, 18 showed 
a 6-fold improvement in potency compared with the parent compound 
(Table 5).
After resolution by chiral high-performance liquid chromatography 
(HPLC), biological evaluation against DNA-PK of each pair of 
atropisomers showed that DNA-PK inhibitory activity resided 
exclusively in the (−)-atropisomer enantiomer, with the antipodal 
(+)-atropisomer proving inactive at 100 µM [29,35] (Scheme 5).
Phenol related IC series
Reported by the ICOS Corporation and Array Biopharma as part 
of a new series of DNA-PK inhibitors, 2-hydroxy-4-morpholin-4-
yl-benzaldehyde (IC60211, IC50=400 nM) (19) is a representative 
example of DNA-PK inhibitors possessing a morpholine motif [36]. 
Optimisation of 19 led to the identification of a number of selective 
inhibitors (all maintaining the critical arylmorpholine substructure), 
including IC87361 (20), found to be 50-fold more selective for DNA-
PK than for p110β [36,37] (Table 6 and Scheme 6).
It has been demonstrated in animal models, that compounds in 
this series are relatively nontoxic and have improved pharmacokinetic 
profiles over other specific DNA-PK inhibitors, while enhancing the 
efficacy of IR in vitro and in vivo [37,38].
SU11752
In their efforts towards developing a specific DNA-PK inhibitor, 
Sugen researchers employed a screening campaign of 3-substituted 
indolin-2-ones and successfully identified the ATP-competitive DNA-
PK inhibitor SU11752 (21). Compound 21 showed good potency 
against DNA-PK (IC50=0.13 ± 0.028 µM) and selectivity for DNA-PK 
over PI3K (p110γ; IC50=1.10 µM) [39] (Scheme 7).
VX-984
VX-984 (22), disclosed by Vertex Pharmaceuticals, is a DNA-PK 
inhibitor currently undergoing a phase I clinical study, in combination 
with pegylated liposomal doxorubicin in patients with advanced solid 
tumours or lymphomas. Compound 22 has an IC50 of 88 ± 64 nM for 
inhibition of DNA-PKcs autophosphorylation (Ser2056) in A549 lung 
cancer cells, with good selectivity versus other PI3K family members 
[40] (Scheme 8).
DNA-PK PI3K PI4Kβ ATM ATR mTOR
IC50(µM) 0.012 5 40 >100 >100 1.7
Table 3: NU7441 (13) inhibitory activity against different kinases of the PIKK family.
Scheme 6: Phenol related IC series.
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Scheme 7: ATP-competitive DNA-PK inhibitor SU11752 (21).
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Scheme 5: Antipodal (+)-atropisomer proving inactive at 100 µM.
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R1 R2 DNA-PK inhibition
13 H H 0.03
17 Me H 1.7
17-(−) Me H 1.2
17-(+) Me H 100
18 H Me 0.005
18-(−) H Me 0.002
18-(+) H Me 7
Table 5: Inhibition of DNA-PK (IC50 µM) by 3-substituted dibenzothiophen-4-yl 
derivatives and 7-substituted chromen-4-one derivatives.
Table 6: Activity of DNA-PK inhibitors 19 and 20 (IC50 nM) against various PI3Ks 
[36,37].
DNA-PK p110α p110β p110δ p110γ
19 400 10000 2800 5100 37000
20 34 3800 1700 2800 7900
Table 4: Properties of NU7441 (13) and KU-0060648 (14) (Data are the mean ± the 
standard deviation or individual values; adapted from Ref [30]).
Assay Data 13 14
Enzyme DNA-PK IC50 (nM) 42 ± 2 5.0 ± 1
Cellular
(HeLa)
pDNA-PK EC50 (nM) 212, 339 136 ± 17
DMR (0.1 μM DNA-PK inhibitor) 2.2 ± 0.2 4.0 ± 0.4
DMR (0.5 μM  DNA-PK inhibitor) 2.8 ± 0.1 13 ± 2
Other LogD (pH=7.4)
hERG IC50 (μM) 
>4.3
14, 19
3.05
>20
Solubility at pH 7.4 (μM) <0.3, <0.2 161 ± 103a
Human plasma protein binding (% Free)
CYP450 inhibition (μM)
b
0.04, 0.17
-
6.2, 3.6
>10
DMR, the dose modification ratio, defined as the percentage of cell survival in 
the absence of compound with 2 Gy treatment divided by that in the presence of 
compound plus 2Gy treatment as determined in 6-8 day clonogenic assays; logD, 
the distribution coefficient calculated as the ratio for the sum of all species of a 
compound in 1-octanol versus that in water at equilibrium; hERG, the human ether-
a-go-go-related gene.
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Scheme 9: M3814 (23).
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M3814
Merck researchers have developed M3814 (23, also described 
as MSC2490484A), a highly potent and selective inhibitor of DNA-
PK [41]. In April 2017, information relating to the structure of the 
compound was released into the public domain [42]. M3814 entered 
phase I clinical development in December 2014 (NCT02316197) for use 
in patients with solid tumours who had DNA repair deficiencies, and 
in patients with Chronic Lymphocytic Leukaemia. M3814 later entered 
phase I trials in July 2015 (NCT02516813) in combination with DNA 
damaging modalities such as radio-chemotherapy and radiation. The 
ongoing trial incorporates a proof-of-principle study to examine the 
pharmacodynamic and mechanistic consequences of drug treatment. 
Disclosure of results by Merck in 2016, indicated that M3814 is active in 
a preclinical setting, exhibiting efficacy in all mouse models of human 
cancer, in combination with IR [41,43] (Scheme 9).
Conclusion
DNA-PK has all the potential hallmarks of an appealing and 
interesting therapeutic target, given its role in chemo- and radio-
resistance and implication in tumourigenesis, that the protein possesses 
a druggable kinase domain that is critical for DSB repair, that there 
are potential markers for assessing the pharmacodynamic activity of 
an inhibitor, and that additional markers of DSB repair are available 
to provide direct proof-of-mechanism. Previous investment made by 
academia and pharma alike, to identify inhibitors of DNA-PKcs activity 
has resulted in the identification of candidate drugs that are currently 
being tested clinically, as monotherapy and in combination with 
chemotherapy or radiotherapy. This progress may enable us to shortly 
realise the potential of exploiting DNA-PK inhibition for the benefit of 
cancer patients.
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